Introduction: BrainAge models based on neuroimaging data have diagnostic classification power but have replicability issues due to site and patient variability. BrainAge models trained on neuropsychological tests could help distinguish stable mild cognitive impairment (sMCI) from progressive MCI (pMCI) to Alzheimer's disease (AD).
Methods: A linear regressor BrainAge model was trained on healthy controls using neuropsychological tests and neuroimaging features separately. The BrainAge delta, predicted age minus chronological age, was used to distinguish between sMCI and pMCI.
Results: The cross-validated area under the receiver-operating characteristic (ROC) curve for sMCI versus pMCI was 0.91 for neuropsychological features in contrast to 0.68 for neuroimaging features. The BrainAge delta was correlated with the time to conversion, the time taken for a pMCI subject to convert to AD.
Discussion: The BrainAge delta from neuropsychological tests is a good biomarker to distinguish between sMCI and pMCI. Other neurological and psychiatric disorders could be studied using this strategy.
Highlights: BrainAge models based on neuropsychological tests outperform models based on neuroimaging features when distinguishing between stable mild cognitive impairment (sMCI) from progressive MCI (pMCI) to Alzheimer's disease (AD).The combination of neuropsychological tests with neuroimaging features does not lead to an improvement in sMCI versus pMCI classification compared to using neuropsychological tests on their own.BrainAge delta of both neuroimaging and neuropsychological models was correlated with the time to conversion, the time taken for a pMCI subject to convert to AD.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614125 | PMC |
| http://dx.doi.org/10.1002/dad2.12493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[The relationship between neuropsychological indicators and neuroimaging changes according to MRI morphometry in patients with Alzheimer's disease and glaucoma].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Federal Center of Brain Research and Neurotechnologies, Moscow, Russia.
Objective: Study of neuroimaging changes according to MRI morphometry and their comparison with the structure and severity of cognitive impairment (CI) in patients with Alzheimer's disease (AD) and primary open-angle glaucoma (POAG).
Material And Methods: The study involved 90 patients who were divided into two equal groups of 45 people and who early had diagnosis of AD (group 1; median age - 71 [66; 77] years) and POAG (group 2; median age - 68 [64; 77] years). 71] years).
Apolipoprotein E epsilon4 allele is associated with better performance language and visual memory in spinocerebellar ataxia type 3.
Eur J Neurol
January 2025
School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Background: The regulatory role of the apolipoprotein E (APOE) ε4 allele in the clinical manifestations of spinocerebellar ataxia type 3 (SCA3) remains unclear. This study aimed to evaluate the impact of the APOE ε4 allele on cognitive and motor functions in SCA3 patients.
Methods: This study included 281 unrelated SCA3 patients and 182 controls.
The effect of eye movement desensitization on neurocognitive functioning compared to retrieval-only in PTSD patients: a randomized controlled trial.
BMC Psychiatry
December 2024
Department of Clinical, Neuro- and Developmental Psychology, Faculty of Behavioral and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Background: There is robust evidence that posttraumatic stress disorder (PTSD) is associated with neurocognitive deficits, such as executive dysfunction or memory dysfunction. Eye Movement Desensitization and Reprocessing (EMDR) is an evidence-based treatment for PTSD, in which eye movements (EMs) are performed during traumatic memory retrieval. We examined whether Eye Movement Desensitization (EMD) improves neurocognitive functioning in PTSD patients, in comparison with a retrieval-only control condition without EMs.
View Article and Find Full Text PDFAssociation of plasma BDNF and MMP-9 levels with mild cognitive impairment: a matched case-control study.
Sci Rep
December 2024
Department of Public Health, School of Medicine, Shihezi University, Shihezi, Xinjiang, China.
The prevalence of Alzheimer's disease (AD) is on the rise globally, and everyone who develops AD eventually experiences mild cognitive impairment (MCI) first. Timely intervention at an early stage of the disease may mitigate disease progression. Recent studies indicate that BDNF and MMP-9 play a significant role in the pathogenesis of AD.
View Article and Find Full Text PDFValidation of the Edinburgh postnatal depression scale and prevalence of depression among adolescent mothers in a Cameroonian context.
Sci Rep
December 2024
Actions en Santé Publique, 1204, Geneva, Switzerland.
The Edinburgh Postnatal Depression Scale (EPDS) is the screening tool for perinatal depression, and its cut-off score varies according to context and population. In Cameroon, no study has yet defined a cut-off score or the prevalence of perinatal depression in adolescent mothers. Our aim is to determine the cut-off for teenage mothers in Cameroon.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!